CAR T-cell Therapy for Solid Tumors?

Cancer Discovery, 2018

687 citations recorded by the source corpus.

Scientists have identified a wide variety of challenges preventing the development of effective CAR T-cell therapies for solid tumors, but they are investigating just as many potential solutions. Progress has been slow, but many researchers remain optimistic that successful CAR T-cell therapies, either alone or in combination with other treatments, will eventually be developed.

Subfields: Biomedical Engineering, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/ebd028d9bc8ce42b003e7268709746008a737ad6

Citations in the corpus

• Smart nanoparticles for cancer therapy (2023, background): “329 Additionally, the environment and host of supplied live cells play a signi fi cant role in the survivability, durability, and maintenance of bene fi cial cell phenotypes.”
• A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. (2019, background): “, 2018), CAR-T cell immunotherapy in solid tumors has not been as effective and remains to be further developed (Newick et al., 2017).”
• From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review) (2018, positive): “A novel development involves modern gene transfer technologies, which allow the production of T-cells with TAA‑specific TCRs (4) or with CAR, which consist of antibody binding sites fused to TCR signaling chains (70).”
• CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment (2019, background): “factor receptor 1) Lung, prostate (1, 34) Preclinical –”